<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562428</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH109-REC1-085</org_study_id>
    <nct_id>NCT04562428</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial</brief_title>
  <official_title>The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi&#xD;
      Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase&#xD;
      inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of&#xD;
      life in advanced hepatocellular carcinoma patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the top fourth most common cancer in Taiwan. Approximately&#xD;
      85% of cases of HCC patients had chronic HBV or HCV infection in Taiwan. Metabolic risk&#xD;
      factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated&#xD;
      with increased risk for nonviral hepatocellular carcinoma.&#xD;
&#xD;
      The first and second-line systemic therapy approved in advanced hepatocellular carcinoma are&#xD;
      multikinase inhubitors .Sorafenib (Nexavar)、Regorafenib and Lenvatinib are significantly&#xD;
      improve survival in patients who had unresectable advanced and/or metastatic HCC not amenable&#xD;
      to local treatment methods. General fatigue, poor appetite and pain are regarded as common&#xD;
      and unavoidable side effect experienced during the course of cancer and its treatment.&#xD;
      Anorexia is a common cause of malnutrition and is associated with negative effects on the&#xD;
      quality of life (QOL) for patients with cancer. However, quality of life as a prognostic&#xD;
      factor for survival in hepatocellular carcinoma. Management of appetite is the key to&#xD;
      improving both the QOL and the prognosis for such patients.&#xD;
&#xD;
      Cancer-related anorexia and target therapy-induced anorexia is very important in HCC&#xD;
      patients. According to Chinese medicine theory., &quot;spleen-deficiency, qi-stagnation and&#xD;
      dampness&quot; are the most common syndrome in advanced hepatocellular carcinoma patients. Thus,&#xD;
      the principles of Chinese medicine treatment are invigorating Pi, regulating qi, dissipating&#xD;
      dampness and appetizing wei. Most patients received traditional Chinese medicine treatment as&#xD;
      adjuvant therapy to alleviate cancer symptoms, diminishing the side effects and complications&#xD;
      of treatment course at late stages. The purpose of the study was search the safety and&#xD;
      efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular&#xD;
      carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment&#xD;
      effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma&#xD;
      patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>patient body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EORTC QLQ-C30 score</measure>
    <time_frame>8 weeks</time_frame>
    <description>European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EORTC QLQ-HCC18</measure>
    <time_frame>8 weeks</time_frame>
    <description>European Organization for Research and Treatment of Hepatocellular carcinoma Core Quality of Life Questionnaire score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CASQ</measure>
    <time_frame>8 weeks</time_frame>
    <description>cancer appetite and symptom questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FACT-G</measure>
    <time_frame>8 weeks</time_frame>
    <description>Functional Assessment of Cancer Therapy - General</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CCMQ</measure>
    <time_frame>8 weeks</time_frame>
    <description>Chinese medicine questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tong diagnosis</measure>
    <time_frame>8 weeks</time_frame>
    <description>tong diagnosis by Automatic Tongue Diagnosis System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse diagnosis</measure>
    <time_frame>8 weeks</time_frame>
    <description>pulse diagnosis by Huang's Sphygmography in Frequeny-domained Parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>XSLJZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XSLJZ Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiang Sha Liu Jun Zi Decoction dry powder</intervention_name>
    <description>the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei</description>
    <arm_group_label>XSLJZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XSLJZ Placebo</intervention_name>
    <description>XSLJZ Placebo</description>
    <arm_group_label>XSLJZ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced hepatocellular carcinoma patient&#xD;
&#xD;
          2. use multiple protein kinase inhibitor therapy paid by National Health Care Insurance&#xD;
             system (NHCIS) in Taiwan&#xD;
&#xD;
          3. Child-Pugh A class&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status of 0-2&#xD;
&#xD;
          5. survival period over 3 months&#xD;
&#xD;
          6. used Xiang Sha Liu Jun Zi Decoction for one month before the multiple protein kinase&#xD;
             inhibitor therapystarting point&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. combine other cancer at the same time&#xD;
&#xD;
          2. ESRD under dialysis&#xD;
&#xD;
          3. heart disease,CHF、CAD、arrhythmia、hypertension (SBP&gt;150mmHg，DSP&gt;90 mmHg)&#xD;
&#xD;
          4. current serious infection&#xD;
&#xD;
          5. GI bleeding within 30 days&#xD;
&#xD;
          6. receive organ transplant&#xD;
&#xD;
          7. Child-Pugh Class B or C liver status。&#xD;
&#xD;
          8. Refractory Ascites in Liver Cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YuanChing Liao</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medial University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University hospital</name>
      <address>
        <city>Taichung</city>
        <state>西屯區</state>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>multiple protein kinase inhibitor therapy</keyword>
  <keyword>Xiang Sha Liu Jun Zi Decoction</keyword>
  <keyword>appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

